In my 7/16/09 blog, I wrote described company “x” in “How does one anticipate the pitfalls of sustainability” as I was left scratching my head about
The struggling biotech which had filed for bankruptcy has signed off on the court’s transaction for $4 M. In addition to buying substantially all of Biopure’s assets, OPK also agreed to acquire Biopure’s 50% stake in a partnership that owns its headquarters and some laboratory space. That transaction will cost OPK $850,000. Read more…
Investors are now asking more questions about the short, near and long term viability of healthcare stocks. In a slowly rebounding market, despite today’s volatility; there is a silver lining; smaller, leaner healthcare companies are emerging stronger from the past crisis.
There is no quick fix … Read more…
Scientists, managements and investors get excited by a candidate compound’s potential; but
Cash is king … in this environment. But, can too much cash be a “perceived” as a “liability” in light of mounting losses?
Every time the markets rebound, investors deliberate whether this marks the bottom for share pricing and if so, might it be time to get in. However, for those of us who remain skeptical; we have seen too many spikes in momentum, resistance, confidence and resilience as second quarter earnings were good but will it last? Valuations provide indicators when compared to the rapid decline and slow moves to present market levels.
What does it mean? A newly resurrected term from Warren Buffett refers to executives using their own money to personally purchase and hold large stakes stock in the company they run. Executive staff members can talk all they want about confidence in their future prospects and platforms, but the best vote of leadership is putting their a percentage of their net worth on the line just like their investors!
What CEO doesn’t “feel” his suffering share pricing? Read more…
Unfortunately, many small cap healthcare companies have over-exposure to warrants, options and preferred stock of past toxic financings Read more…
How do we define the differences between justified risks and irresponsibility? Boards of Directors (BODs) have responsibilities but, are they exercising their proper fiduciary role in monitoring enterprise development, risk definition and shareholder interests?The financial crisis has heightened the issues of sustainability. BODs of small cap companies are now subject to even more risks associated with …
Founder and Director of Research, Henry McCusker enters his eighth (8) year at Scimitar Equity with past experience in sell-side analysis, buy-side management, corporate management and due diligence.